title: Time course of changes in the concentrations of monoamines in the brain structures of pentylenetetrazole-kindled rats.
abstract: This work attempted to "biochemically" map the brain structures that are recruited at the different stages of pentylenetetrazole (PTZ) kindling (in a model of temporal lobe epilepsy induced by a repeated, systemic administration of PTZ, at a subconvulsive dose of 35 mg/kg). We observed substantial changes in the levels of noradrenaline (NA), 5-hydroxytryptamine (5-HT), dopamine (DA), and their metabolites in the brain structures known to be recruited in the course of kindling, i.e., the piriform, entorhinal and prefrontal cortices, and the hippocampus (in vitro). Kindling of seizures induced time-, seizure-, and structure-dependent increases in the local levels of NA, 5-HT, 5-hydroxyindolacetic acid, DA, homovanillic acid, and 3,4-dihydroxyphenylacetic acid. Surprisingly, limited changes in monoamines (NA and 5-HT) were found in the amygdala. The most potent and widespread effects concerned the serotonergic system, indicating a possible protective role of its enhanced activity in the control of the kindling of seizures. These new data indicate a pattern of changes in the basal activity of local monoaminergic innervation of brain limbic structures, accompanying the induction and propagation of seizures.
authors.affiliation: Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 26/28 Krakowskie Przedmieście Street, 00-927 Warsaw, Poland. jszyndler@yahoo.com
authors.forename: Janusz
authors.initials: J
authors.lastname: Szyndler
authors.forename: Piotr
authors.initials: P
authors.lastname: Maciejak
authors.forename: Danuta
authors.initials: D
authors.lastname: Turzyńska
authors.forename: Alicja
authors.initials: A
authors.lastname: Sobolewska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Bidziński
authors.forename: Adam
authors.initials: A
authors.lastname: Płaźnik
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004195:Disease Models, Animal; D004563:Electrochemistry / Q000379:methods; D007696:Kindling, Neurologic / Q000187:drug effects*; D008297:Male; D010433:Pentylenetetrazole / Q000009:adverse effects*; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D013997:Time Factors
chemical_list: D015306:Biogenic Monoamines; D010433:Pentylenetetrazole
references.citation: Neuroscience. 1990;34(1):209-17
references.pmid: 2139189
references.citation: Epilepsy Res. 2007 Sep;76(2-3):93-102
references.pmid: 17689928
references.citation: Pharmacol Biochem Behav. 2000 Jun;66(2):425-8
references.pmid: 10880700
references.citation: Eur J Pharmacol. 1998 Jun 5;350(2-3):181-8
references.pmid: 9696406
references.citation: Synapse. 1997 Aug;26(4):351-8
references.pmid: 9215594
references.citation: Proc Natl Acad Sci U S A. 1987 Dec;84(23):8712-5
references.pmid: 3120197
references.citation: Life Sci. 1996;59(21):1763-71
references.pmid: 8937503
references.citation: Br J Pharmacol. 2001 Oct;134(3):507-20
references.pmid: 11588104
references.citation: J Neurochem. 1992 Nov;59(5):1702-8
references.pmid: 1402915
references.citation: Ann N Y Acad Sci. 1978 Jun 12;305:437-56
references.pmid: 280255
references.citation: Neurochem Res. 1994 Sep;19(9):1139-43
references.pmid: 7824066
references.citation: Brain Res. 1994 Jul 18;651(1-2):337-41
references.pmid: 7922584
references.citation: Exp Neurol. 1986 Nov;94(2):379-90
references.pmid: 3095132
references.citation: Psychopharmacology (Berl). 1990;100(1):60-5
references.pmid: 1688661
references.citation: Epilepsy Behav. 2005 Dec;7(4):602-19
references.pmid: 16169281
references.citation: Eur J Pharmacol. 1992 Nov 10;222(2-3):227-32
references.pmid: 1451735
references.citation: J Chromatogr. 1986 Jun 6;360(1):211-8
references.pmid: 3733945
references.citation: Brain Res. 1992 Jul 3;584(1-2):36-44
references.pmid: 1515952
references.citation: Brain Res. 1997 Feb 7;747(2):338-42
references.pmid: 9046012
references.citation: J Neurochem. 2004 May;89(4):834-43
references.pmid: 15140183
references.citation: Exp Neurol. 1979 Mar;63(3):527-44
references.pmid: 428481
references.citation: Neuropharmacology. 1988 Oct;27(10):1081-4
references.pmid: 3148871
references.citation: Brain Res. 1995 Jan 16;669(2):176-82
references.pmid: 7712172
references.citation: J Pharmacol Exp Ther. 1992 Feb;260(2):533-40
references.pmid: 1738103
references.citation: Neurology. 2002 Apr 23;58(8 Suppl 5):S27-39
references.pmid: 11971130
references.citation: Brain Res Bull. 1979 Jan-Feb;4(1):1-7
references.pmid: 157185
references.citation: Brain Res. 1986 Oct 22;385(2):212-8
references.pmid: 2430666
references.citation: Neuropharmacology. 1984 Sep;23(9):1041-8
references.pmid: 6083501
references.citation: Synapse. 1996 Feb;22(2):159-94
references.pmid: 8787131
references.citation: Crit Rev Neurobiol. 1999;13(4):317-56
references.pmid: 11028680
references.citation: Exp Neurol. 1982 Oct;78(1):158-66
references.pmid: 7117477
references.citation: Neuroscience. 1993 Mar;53(2):425-31
references.pmid: 8098511
references.citation: Brain Res. 1993 Jan 8;600(1):63-73
references.pmid: 8422591
references.citation: J Neurophysiol. 1986 Jun;55(6):1295-307
references.pmid: 3016209
references.citation: Epilepsia. 1998 Jul;39(7):709-14
references.pmid: 9670898
references.citation: Epilepsia. 1993 Mar-Apr;34(2):381-4
references.pmid: 8384110
references.citation: Neuropsychopharmacology. 1992 Nov;7(3):189-95
references.pmid: 1382432
references.citation: Neurology. 1995 Oct;45(10):1926-7
references.pmid: 7477995
references.citation: Exp Neurol. 1982 Sep;77(3):700-4
references.pmid: 6811306
references.citation: Brain Res. 1975 Aug 22;94(1):115-131
references.pmid: 167913
references.citation: Epilepsia. 1982 Aug;23(4):359-66
references.pmid: 6284498
references.citation: Nature. 1987 Jul 2-8;328(6125):73-7
references.pmid: 3600775
references.citation: Epilepsy Res. 1987 Jan;1(1):40-5
references.pmid: 3504382
references.citation: J Neural Transm Park Dis Dement Sect. 1993;5(2):89-100
references.pmid: 8101446
references.citation: Neuroscience. 2004;126(3):727-41
references.pmid: 15183521
references.citation: J Pharmacol Exp Ther. 1989 Apr;249(1):229-35
references.pmid: 2709332
references.citation: Brain Res. 1972 Nov 27;47(1):262-8
references.pmid: 4641271
references.citation: Neuropharmacology. 1973 Jul;12(7):681-92
references.pmid: 4730377
references.citation: Brain Res. 2001 Feb 16;892(1):176-92
references.pmid: 11172762
references.citation: Epilepsy Behav. 2009 Oct;16(2):216-24
references.pmid: 19713157
references.citation: Br J Pharmacol. 1995 Aug;115(7):1314-8
references.pmid: 7582562
references.citation: Pharmacol Toxicol. 1993 Apr-May;72(4-5):213-20
references.pmid: 8103921
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1995 Sep;19(5):917-30
references.pmid: 8539428
references.citation: Epilepsy Res. 2008 Dec;82(2-3):194-9
references.pmid: 18845420
references.citation: Neurosci Lett. 1999 Feb 12;261(1-2):89-92
references.pmid: 10081934